RNXT
RenovoRx Inc
1.50$
-7.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -58.3% | +226.6% | +150.7% | -16.4% | -19.1% | +97.3% | -14.8% | -17.9% | -27.8% | +72.5% | -17.8% | |
| – | -58.3% | +217.9% | +157.6% | -16.4% | -22.0% | +101.1% | -14.9% | -18.0% | -28.1% | +73.8% | -21.2% | |
| – | -63.6% | +274.2% | +167.5% | -18.6% | -25.2% | +103.8% | -15.6% | -18.4% | -30.1% | +76.0% | -23.3% | |
| – | – | – | +167.5% | -18.6% | – | – | -15.6% | -18.4% | -30.1% | +76.0% | -23.3% | |
| – | – | – | – | – | – | +462.8% | +50.0% | -53.4% | -17.8% | +101.4% | +71.4% | |
| – | – | – | – | – | – | – | – | – | -30.5% | +100.5% | +1.1% | |
| – | +27.1% | -32.4% | -9.6% | +8.3% | +23.0% | -21.5% | +5.1% | +4.2% | -14.5% | +1.0% | -7.6% | |
| – | -26.8% | +157.1% | -56.6% | +35.2% | +7.7% | -9.1% | -10.4% | +21.1% | +4.1% | -2.1% | -1.9% | |
| – | – | – | – | – | – | – | +2.1% | +3.0% | +2.9% | +2.9% | – | |
| – | +60.3% | -36.5% | +23.0% | +56.6% | -14.6% | +65.0% | -30.6% | +29.5% | -8.1% | +40.1% | -22.6% | |
| – | -50,100.0% | – | +424.7% | -23.7% | -36.7% | +193.8% | -19.1% | -24.1% | -32.9% | +107.8% | -20.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -50.0% | +179.6% | -19.6% | +3.7% | -3.6% | +30.6% | +16.5% | +0.2% | -3.6% | +7.6% | +24.4% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.